Biopharma Business

Tag "RAS-peptide immunotherapy"

First patient recruited in Phase Ib trial of TG02

The first patient has been recruited in an exploratory Phase Ib clinical trial of Targovax’s second product from its RAS-peptide immunotherapy platform, TG02. In the open-label, non-randomised trial — to

Read Full Article

Upcoming Events

[eventlist]

The Magazine

New Subscriber

Subscribe Here



Advertisements